Literature DB >> 2465307

Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease.

A M Suikkari1, K Ruutiainen, R Erkkola, M Seppälä.   

Abstract

Insulin-like growth factors IGF-I and IGF-II are bound to specific binding proteins in serum. The lower mol. wt binding protein (IGF-BP) has been detected in various tissues, including secretory endometrium and preovulatory follicles of the ovary. This group studied the circulating levels of IGF-BP in the serum of 23 patients with polycystic ovarian disease (PCOD) and found that one-third of them have a subnormal level. In comparison with PCOD patients with a normal level, those with a subnormal level had a higher degree of obesity and a tendency to be more hirsute. They also had a higher serum insulin concentration and testosterone/sex hormone-binding globulin (SHBG) ratio, but lower serum SHBG concentration than those with a normal IGF-BP level. PCOD is the second abnormal clinical condition, after insulinoma, in which subnormal serum IGF-BP concentrations have been reported. The significance of low serum IGF-BP levels to pathophysiology of PCOD remains to be elucidated by studies on local interaction between IGF-BP and insulin in the polycystic ovary.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2465307     DOI: 10.1093/oxfordjournals.humrep.a136858

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  12 in total

Review 1.  Growth factors in the ovary.

Authors:  G Giordano; A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

Review 2.  Implantation failure: molecular mechanisms and clinical treatment.

Authors:  Hakan Cakmak; Hugh S Taylor
Journal:  Hum Reprod Update       Date:  2010-08-21       Impact factor: 15.610

3.  [In Process Citation]

Authors:  Jonette E Keri; Adena E Rosenblatt
Journal:  J Clin Aesthet Dermatol       Date:  2008-09

4.  Metformin: direct inhibition of rat ovarian theca-interstitial cell proliferation.

Authors:  Matthew A Will; Murugesan Palaniappan; Helle Peegel; Pradeep Kayampilly; K M J Menon
Journal:  Fertil Steril       Date:  2012-05-17       Impact factor: 7.329

Review 5.  Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation.

Authors:  Maureen M B Schulte; Jui-he Tsai; Kelle H Moley
Journal:  Reprod Sci       Date:  2014-12-07       Impact factor: 3.060

Review 6.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

Review 7.  HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome?

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Statins in the treatment of polycystic ovary syndrome.

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Semin Reprod Med       Date:  2008-01       Impact factor: 1.303

9.  Polycystic Ovary Syndrome and the Forgotten Uterus.

Authors:  Pardis Hosseinzadeh; Maya Barsky; William E Gibbons; Chellakkan S Blesson
Journal:  F S Rev       Date:  2020-12-13

10.  The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep.

Authors:  Kirsten Hogg; Charlotte Wood; Alan S McNeilly; W Colin Duncan
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.